You are here

  • Home
  • Archive
  • Volume 75, Issue Suppl 2
  • FRI0222 Pharmacokinetics, Pharmacodynamics, Safety and Efficacy of Proposed Rituximab Biosimilar (GP2013) vs. EU-Approved Rituximab (RTX) in Patients with Rheumatoid Arthritis: Results from A Randomized Controlled Trial (GP13-201) over 52 Weeks

Share

Article menu

Download PDFPDF

Poster Presentations
Rheumatoid arthritis - other biologic treatment
FRI0222 Pharmacokinetics, Pharmacodynamics, Safety and Efficacy of Proposed Rituximab Biosimilar (GP2013) vs. EU-Approved Rituximab (RTX) in Patients with Rheumatoid Arthritis: Results from A Randomized Controlled Trial (GP13-201) over 52 Weeks

Share this article

Click the icon of the social media platform on which you would like to share this article.

Twitter logo Facebook logo LinkedIn logo

Email this article to a friend

We will not keep your email address; we ask for it so your friend knows the email isn't spam.
Enter multiple addresses on separate lines or separate them with commas.
FRI0222 Pharmacokinetics, Pharmacodynamics, Safety and Efficacy of Proposed Rituximab Biosimilar (GP2013) vs. EU-Approved Rituximab (RTX) in Patients with Rheumatoid Arthritis: Results from A Randomized Controlled Trial (GP13-201) over 52 Weeks
(Your Name) has forwarded a page to you from Annals of the Rheumatic Diseases
(Your Name) thought you would like to see this page from the Annals of the Rheumatic Diseases web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.